No Data
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.
① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?
Earnings Preview: TIGERMED to Report Financial Results on April 28
Some Confidence Is Lacking In Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) As Shares Slide 26%
Has the SSE Health Care theme Index risen again? This year, the public fund performance has shuffled, with the highest return of the health care theme Fund exceeding 44%, and Inflow of capital has accelerated.
As of April 16, two SSE Health Care theme Index Funds have entered the top 10 performances of actively managed equity funds this year; Since April, multiple Hwabao WP CSI Medical Service ETFs have seen significant net subscriptions, with the total amount of fund shares for these medical ETFs reaching a new high; Fund managers believe that the pharmaceutical sector is not just undervalued in parts, but is comprehensively undervalued, and the nature of Innovative Drugs has changed.
TIGERMED (300347.SZ): The current tariff policy in the USA mainly imposes additional duties on products, but it has no significant impact on the company at this time.
On April 15, Gelonghui reported that TIGERMED (300347.SZ) stated on the interactive platform that the company is a contract research organization (CRO) focused on providing comprehensive Professional Services for the entire process of clinical trials for new drug development. It offers comprehensive and integrated clinical research solutions for Global pharmaceutical and medical instruments innovation companies. The services primarily include clinical trial technical services and related laboratory services. Currently, the USA's tariff policy primarily imposes additional tariffs on products, which has no significant impact on the company. The company will continue to monitor the developments in USA's tariff policy.
